RxDoctor Payments Data

James Miyazaki

Family · Caldwell, IDNPI 1740596873

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,144in general payments, 2019–2025

Across 279 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$799
  • Lilly USA, LLC$734
  • Boehringer Ingelheim$468
  • AstraZeneca$403
  • Merck$303
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$6,144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,144 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$25,878
Albuterol Sulfate HfaAlbuterol Sulfate80$2,255
Losartan Potassium35$594
Atorvastatin Calcium52$553
Tamsulosin Hcl19$443
Amlodipine Besylate53$361
Metformin Hcl51$338
Cyclobenzaprine Hcl20$323
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$301
Alendronate Sodium29$293
Ibuprofen14$194
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$190
Mupirocin40$184
Hydroxyzine Hcl17$175
Lisinopril27$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$799$25,87825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Idaho.

Other family in Caldwell

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →